Nevro (NYSE:NVRO) recently announced that its board is exploring strategic options as it faces increased competition in the spinal cord stimulation space. In Nevro’s Aug. 6 earnings release call, CEO Kevin Thornal said the company over the next several months will more aggressively explore broader options alongside the company’s present stand-alone path. “These opportunities may […]
Nevro Corp.
Nevro promotes new chief operating officer from within
Nevro (NYSE:NVRO) announced that it appointed Christofer Christoforou as its new chief operating officer, effective May 15. Christoforou, 54, initially joined the spinal cord stimulation technology developer in June 2016. He previously served as Nevro’s SVP of technical operations. Prior to Nevro, he served as VP, quality engineering, at Thoratec, a medical device company. There, […]
FDA clears sacroiliac joint fusion device from Nevro
Nevro (NYSE:NVRO) announced today that the FDA cleared its sacroiliac (SI) joint fusion device without the need to include an accompanying screw. Redwood City, California-based Nevro plans to market this device as Nevro1, without the need for the NevroFix screw. The system aims to immediately transfix the SI joint, allowing the opportunity for long-term fusion. […]
Layoffs in medtech: These companies recently reduced their workforce
The workforce reduction trend has swept the economy recently, and unfortunately, the medtech space is not immune to layoffs. You’ve probably read about the ongoing layoffs sweeping the tech industry, media and more. For instance, Yahoo, Disney, Zoom and more all reported workforce reductions as companies across industries grapple with economic pressures. Think inflation, supply […]
How does medtech CEO compensation compare?
Medtech CEO compensation averaged $10.5 million during the companies’ most recent fiscal years. That number from our recent MassDevice analysis may seem like a lot to an average person — but not as much in the world of corporate CEOs. In fact, the average compensation of S&P 500 company CEOs was $25.2 million in 2022, […]
Nevro earns coverage win for spinal cord stimulation
Nevro (NYSE:NVRO) announced that Carelon Healthcare plans to expand its spinal cord stimulation (SCS) coverage. Carelon plans to publish a new interventional pain management policy expanding SCS coverage for painful diabetic neuropathy (PDN). The policy, set to go into effect on April 14, increases PDN patient coverage by nearly 43 million additional lives. Payers that […]
Nevro announces layoffs
Pain-treatment device company Nevro (NYSE:NVRO) announced that it is letting go of 63 employees, about 5% of its workforce, as part of a restructuring effort. “This restructuring supports our strategy and allows us to focus our investments to further position Nevro for long-term growth and profitability,” Nevro CEO Kevin Thornal said in a news release […]
Nevro acquires joint fusion device maker Vyrsa, closes credit facility and refinancing
Nevro (NYSE:NVRO) announced that it acquired Vyrsa Technologies, a company developing a minimally invasive joint pain treatment. Vyrsa has a portfolio of sacroiliac (SI) joint pain devices for use in SI joint fusion procedures. Established in 2021, the company manufactures and supports a complete portfolio of FDA-cleared devices. Dr. David Caraway, Nevro chief medical officer, […]
2-year data shows painful diabetic neuropathy relief with Nevro spinal cord stimulation
Nevro (NYSE:NVRO) today announced 24-month data from its Senza painful diabetic neuropathy (PDN) spinal cord stimulation (SCS) trial. Redwood City, California-based Nevro published its study results in Diabetes Research and Clinical Practice. The trial evaluated the long-term efficacy of high-frequency 10 kHz SCS to treat refractory PDN. It compared patients receiving the Senza HFX SCS […]
Nevro names new chief commercial officer
Nevro this week announced it appointed Greg Siller as senior VP and chief commercial officer, effective June 19. Siller will replace Niamh Pellegrini, who is leaving the company on June 9. He has spent the last 17 years at Stryker, where he held numerous roles of varying responsibility in sales and marketing. He most recently […]
Nevro enrolls first patient in PDN Sensory study
Nevro this week announced it enrolled the first patient in its painful diabetic neuropathy (PDN) sensory study. The prospective randomized controlled trial will assess the restoration of neurological function as a primary objective in patients with intractable PDN. It will enroll up to 236 patients at multiple sites across the U.S. Patients in the trial […]
